-transparent.png){kind=logo}
Eighty-four previously untreated patients with metastatic adenocarcinoma of the large intestine received intravenous ftorafur at a dosage of 2.25 g/m2/day for 5 consecutive days. Courses were repeated every three weeks. Regressions were noted in 9 of 84 treated patients (11%). Median survival for all patients was 32 weeks. Responders survived only 5 weeks longer than nonresponders; 36 vs. 31 weeks. Central nervous system toxicity was a limiting factor occurring in one-third of patients. Ftorafur in a daily X5 schedule appears not to make a significant contribution to the management of disseminated colorectal cancer.
Related Publications
T Buroker, and
F Padilla, and
C Groppe, and
G Guy, and
J Quagliana, and
J McCracken, and
V K Vaitkevicius, and
B Hoogstraten, and
L Heilbrun
September 1982,
Cancer treatment reports,
T Buroker, and
F Padilla, and
C Groppe, and
G Guy, and
J Quagliana, and
J McCracken, and
V K Vaitkevicius, and
B Hoogstraten, and
L Heilbrun
December 1987,
Cancer treatment reports,
T Buroker, and
F Padilla, and
C Groppe, and
G Guy, and
J Quagliana, and
J McCracken, and
V K Vaitkevicius, and
B Hoogstraten, and
L Heilbrun
May 1983,
Cancer treatment reports,
T Buroker, and
F Padilla, and
C Groppe, and
G Guy, and
J Quagliana, and
J McCracken, and
V K Vaitkevicius, and
B Hoogstraten, and
L Heilbrun
January 1999,
The cancer journal from Scientific American,
T Buroker, and
F Padilla, and
C Groppe, and
G Guy, and
J Quagliana, and
J McCracken, and
V K Vaitkevicius, and
B Hoogstraten, and
L Heilbrun
November 1987,
Cancer treatment reports,
T Buroker, and
F Padilla, and
C Groppe, and
G Guy, and
J Quagliana, and
J McCracken, and
V K Vaitkevicius, and
B Hoogstraten, and
L Heilbrun
February 1993,
Investigational new drugs,
T Buroker, and
F Padilla, and
C Groppe, and
G Guy, and
J Quagliana, and
J McCracken, and
V K Vaitkevicius, and
B Hoogstraten, and
L Heilbrun
February 1993,
Anti-cancer drugs,
T Buroker, and
F Padilla, and
C Groppe, and
G Guy, and
J Quagliana, and
J McCracken, and
V K Vaitkevicius, and
B Hoogstraten, and
L Heilbrun
February 1991,
Investigational new drugs,
T Buroker, and
F Padilla, and
C Groppe, and
G Guy, and
J Quagliana, and
J McCracken, and
V K Vaitkevicius, and
B Hoogstraten, and
L Heilbrun
January 1981,
Cancer treatment reports,
T Buroker, and
F Padilla, and
C Groppe, and
G Guy, and
J Quagliana, and
J McCracken, and
V K Vaitkevicius, and
B Hoogstraten, and
L Heilbrun
July 1976,
Cancer,
